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Background: Treatments in patients with multidrug resistance often involve the use of multiple agents with
partial antiviral activity and overlapping metabolic toxicities. Enfuvirtide is therefore a welcome addition to the
antiretroviral management of patients with multiclass resistant virus, given the low risk of systemic toxicities and
novel mechanism of action relative to existing drug classes.
The aim of this study was to evaluate the effectiveness of ENF plus optimized background regimen (OBR) in a
Mexican cohort of highly HIV-1 ARV-experienced patients.
Methods: Prospective cohort of treatment-experienced HIV-1-infected adults with virological failure who started
therapy with an ENF-containing regimen. The effectiveness of ENF treatment was evaluated with percentages of
undetectable HIV-1 RNA viral load after 24 and 48 weeks of treatment, and changes in CD4+ cell counts.
Results: Forty patients >18 years were included. After 24 weeks of treatment, 91% of patients had HIV-1 RNA viral
load <400 copies/mL and 65.8% had <50 copies/mL. At week 48 of treatment, 81.4% of the patients had HIV-1 RNA
<400 copies/mL and 55.5% had <50 copies/mL; in both cases p <0.0001 compared to baseline. Increase CD4+ cells
were also statistically significant at weeks 24 and 48 with respect to the baseline. Pain at the site of injection was
the main adverse event in 100% of patients.
Conclusion: Our study provides clinically important evidence of the effectiveness and safety of ENF in highly
ARV-experienced HIV-1-infected patients. These findings strengthen the results of previous randomized controlled
trials with this agent.
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Although rates of multiple regimen failure have de-
creased dramatically over the past decade, mortality
rates for those who have experienced failure of at least
two regimens remain high [1]. Some studies have shown
that patients with multidrug failure or multidrug resist-
ance have an overall poor prognosis compared with
those who experience more limited drug failure [2,3].* Correspondence: gloriahuerta@gmail.com
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unless otherwise stated.Enfuvirtide (ENF, also known as T-20) is a novel, syn-
thetic, 36-amino-acid peptide that binds to a region of
the envelope glycoprotein 41 of human immunodefi-
ciency virus (HIV) type 1 (HIV-1), which is involved in
the fusion of the virus with the membrane of the CD4+
host cell. This agent exhibits potent and selective inhib-
ition of HIV-1 in vitro without cytotoxicity [4].
ENF was approved in 2003 as a salvage therapy agent
following the success of the Phase III TORO (T-20 vs
Optimized Regimen Only) clinical trials. TORO 1
(United States, Canada, Mexico, and Brazil) and TORO
2 (Australia and Europe) assessed the safety and efficacy
of ENF plus an optimized background (ENF +OB) ver-
sus optimized background alone (OB) in approximatelytral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and n = 334 OB) [5,6]. RESIST 1 and RESIST 2 trials in-
volved 1509 patients with treatment failure with at least
two protease-inhibitors [7]. Patients were randomized to
take OB plus ritonavir-boosted tipranavir or OB plus a
ritonavir-boosted comparator protease inhibitor (CPI).
Tipranavir/ritonavir had greater response than the con-
trol arm.
When patients had ENF as a part of their OB, response
was improved in both groups. At 48 weeks, 58.5% of
enfuvirtide-na?ve patients in the tipranavir/ritonavir arm
who received enfuvirtide had a treatment response com-
pared with 25.6% of enfuvirtide-na?ve patients randomized
to the control arm and receiving enfuvirtide.
Clinical trials POWER 1 and POWER 2 randomized
highly treatment-experienced patients to ritonavir-boosted
darunavir plus OB or CPI plus OB [8]. At 48 weeks, 61%
of patients in the darunavir/ritonavir arm had a reduction
of plasma viral load of around 1 log(10) copies/mL versus
15% in the CPI arm. This result was more pronounced in
enfuvirtide-na?ve patients who received enfuvirtide plus
boosted darunavir and OB since 81% had a decline in
plasma viral load of >1 log(10) copies/mL, versus 56% of
patients taking boosted darunavir and OB without enfuvir-
tide. Few real life trials have demonstrated the effectiveness
of ENF in highly HIV-1 antiretroviral (ARV)-experienced
patients. The aim of this study was to evaluate the effective-
ness of ENF plus OB regimen (OBR) in a Mexican cohort
of highly HIV-1 ARV-experienced patients.Methods
Design
We developed a prospective cohort of treatment-
experienced HIV-1-infected adults who started therapy
with an ENF-containing regimen. The first end point
occurred after patients completed 24 weeks of treat-
ment. Secondary end point was the evaluation to
48 weeks of treatment.Patients
Patients were >18 years of age with confirmed HIV-1
infection by Enzyme-Linked ImmunoSorbent Assay
(ELISA) and Western blot (WB), virological failure, mu-
tations detected from three classes of antiviral drugs and
na?ve to ENF. Patients had previous treatment with at
least three classes of antiretroviral (ARV) drugs includ-
ing Nucleoside analog reverse-transcriptase inhibitors
(NRTIs), Non-nucleoside reverse-transcriptase inhibitors
(NNRTIs), and Protease inhibitors (PIs), only one patient
had history of integrase inhibitor use (IIN), with muta-
tion resistance documented for each class.
An individualized OBR was chosen for each patient.
The regimen included three to five ARV agents, with ≥2fully active drugs according to HIV-1 resistance testing
and previous antiretroviral drug experience.
Measurements
Clinical history regarding ARV regimens, CD4+ cells
count, HIV-1 RNA viral load, and serum laboratory pa-
rameters at the beginning of the therapy with ENF
(baseline) and at 24 and 48 weeks later was recorded.
Mutations were assessed from plasma HIV-1 pol se-
quences using the Stanford database. The presence of
resistance was defined according to Stanford HIVdb (SS)
ranges as follows: 0? 9 = susceptible; 10? 14 = potential
low-level resistance; 15? 29 = low-level resistance; 30? 59 =
intermediate resistance; and ≥60 = high-level resistance.
The genotype sensitivity score (GSS) was defined as the
total number of drugs (excluding enfuvirtide) in a partici-
pant? s optimized background antiretroviral regimen to
which their HIV isolate had genotypic sensitivity, as de-
duced from gene sequence and mutation analyses. This was
calculated based on the drug resistance scores extracted
from the Stanford HIV data base (HIVdb). Each antiretro-
viral drug (ARV) was assigned a score according to the
five-level Stanford HIVdb interpretation: 1.00, 0.75, 0.50,
0.25 and 0.00 for susceptible, potential low-level resistance,
low-level resistance, intermediate resistance and high-level
resistance. The GSS was the sum of all scores for all ARVs
in the patient? s OBR regimen. The arithmetic sum of the in-
dividual score for the specific drugs provided the total GSS
of that treatment. We classified the total GSS score in the
following categories: 0 to 1, 1 to 2, or ≥2. The 0 to ,1 group
contains viral sequences almost entirely resistant to the
drugs in their regimen, and the ≥2 group contains viral
sequences susceptible to ≥2 drugs given in their OBR
regimen [9].
The effectiveness of ENF treatment was evaluated with
percentages of undetectable HIV-1 RNA viral load
after 24 and 48 weeks of treatment. We also evaluated
changes in CD4+ cell counts.
Tolerability endpoints were drug tolerability, death,
and immune reconstitution and inflammatory syndrome
reactions (ISRs). Other evaluations were changes in
fasting lipids levels (total cholesterol, triglycerides), and
creatinine from baseline to weeks 24 and 48.
Statistical analysis
Baseline characteristics were summarized using medians
and interquartile ranges (IQR) for continuous variables and
proportions for categorical variables. Nonparametric paired
tests were used to evaluated CD4 counts and viral load
changes. Descriptive statistics were used to evaluate
changes in CD4+ cell count and HIV-RNA viral load from
baseline. The following statistics were calculated for con-
tinuous variables: mean, standard deviation, median with
IQR. For categorical variables, number of values in each
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ber of patients in the study population were calculated.
Explorative statistical methods were used regarding the ef-
ficacy endpoints and changes in safety-relevant laboratory
parameters. Significance changes from baseline were
tested using the Wilcoxon signed-rank test. All analyses
were carried out using SPSS software (version 17; SPSS
Inc, Chicago, IL).
Results
We included 40 patients; 37 patients fulfilled the inclu-
sion criteria for the 24-week analyses and 27 of thoseTable 1 Baseline characteristics and optimized background




Mean age, years (?SD) 43 (7.7)
Disease characteristics
Median duration of infection (range) 13 (8? 22)
Median baseline log10 HIV RNA (range) 4.22 (1.80-5.76)
Median CD4+ cells count, cell per mL (range) 177 (20 ? 508)




History of antiretroviral treatment
Median of previous ARV treatments (range) 5 (3 ? 10)
Baseline resistance
Primary IAS-USA [10] PI mutations (range) 2 (0 ? 5)
PI RAMs 3 (1 ? 7)
NRTI RAMs 5 (0 ? 8)
NNRTI RAMs 1 (0 ? 3)




*GSS OBR, Median (IQR) 2.0 (1.50-2.25)
GSS OBR, n (%)
≥2 12 (57.1%)
1 to <2 9 (42.8%)
0 to <1 0 (0%)




DRV = Darunavir, rtv = Ritonavir, TPV = Tipranavir, RAL = Raltegravir, TDF = Tenofovir,
*Genotypic score according to Stanford HIV db.patients were followed through the 48-week analyses.
Two patients died because of advanced disease at the be-
ginning of the ENF regimen (<12 weeks). These deaths
were not associated with ENF treatment.
The median age of the overall cohort at enfuvirtide
initiation was 44.8 years (SD ?8.79) and 89.5% were
men. CDC Class C AIDS was found in 64.8% of patients
and median of previous ARV treatment was 5 (IQR 5 ? 7)
(Table 1). When we analyze OBR according to the Stan-
ford HIVdb, we did not find difference between the SS
of OBR with virological failure and the one who got <50
copies/mL.TPV/rtv + ENF + OBR
(n = 12)





47 (11.2) 45 (6.2) 44.8 (8.79)
13 (5? 19) 14 (5? 19) 13 (5? 22)
4.18 (3.45-5.59) 4.20 (2.54-5.00) 4.22 (1.80-5.76)
301 (74? 561) 119 (8? 339) 224 (8? 561)
1 (8.3%) 0 4 (10.8%)
2 (9.5%) 1 (25%) 9 (24.3%)
9 (42.8%) 3 (75%) 24 (64.8%)
5.5 (4? 12) 5.5 (5? 7) 5 (3? 12)
2 (0? 6) 3 (0? 5) 2 (0? 6)
4.5 (2? 7) 4 (1? 7) 4 (1? 7)
6 (4? 7) 4 (2? 4) 5 (0? 8)
1 (0? 4) 2 (0? 2) 1 (0? 4)
1 (8.3%) 0 1 (2.7%)
8 (66.6%) 1 (25%) 13 (35.1%)
3 (25%) 3 (75%) 23 (62.2%)
1.13 (1.0-1,38) 2.0 (1.63-2.13) 1.50 (1.25-2.00)
0 (0%) 3 (75%) 15 (40.5%)
11 (91.6%) 1 (25%) 21 (56.8%)
1 (8.33%) 0 1 (2.7%)
7 (58%) 3 (75%) 17 (46%)
9 (75%) 4 (100%) 32 (86%)
0 1 (25%) 5 (13.5%)
ETV = Etravirine, PI = proteasa inhibitor, GSS = genotypic susceptibility score,
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without taking into account enfuvirtide was 1.5 (IQR 1.24-
2.0), 1.5 (IQR 1.0-1.63) in patients with failure and 2.0
(IQR 1,25-2,25) in patients with out failure, P = 0.07.
Fifteen (40.5%) patients had a GSS ≥2. Per group, DRV/r
and non-IP OBR group had the mayor proportion of the
patients with GSS ≥2; TPV/r had majority of GSS 1 to <2
regimens (Table 1). None of the ORB groups has a rela-
tionship between the lower GSS and major possibility of
failure (P = 0.23 for DRV/r OBR; P = 0.56 for TPV/r OBR,
and insufficient data for NonIP OBR group). The GSS
1- ≤ 2 at week 48 was associated with viral load grater than
50 copies/ml (p = 0.03), but not with grater than 200
copies/mL (p = 0.12).
At baseline, the median HIV-1-RNA viral load was
17,677 copies/mL [4.24 log(10)] (IQR 3,702 ? 92,555 cop-
ies/mL [3.5 ? 4.9 log(10)]). After 24 weeks of treatment,
91% of patients (n =37) had HIV-1 RNA viral load <400
copies/mL and 65.8% had <50 copies/mL; median, <50
copies/mL [<1.6 log(10)] (IQR <50 ? 137 copies/mL [<1.6 ?
2.1 log(10)]). At week 48 of treatment, 81.4% of the
patients (n = 27) had HIV-1 RNA <400 copies/mL and
55.5% had <50 copies/mL; median, <50 copies/mL [<1.6
log(10)] (IQR <50 ? 185 copies/mL [<1.6? 2.26 log(10)]), in
both cases (p <0.0001 compared to baseline).
At baseline, the median and interquartile range for the
CD4+ cells count were 225 cells/μL (110 ? 478 cells/μL),
whereas at weeks 24 and 48 the values were 301 cells/μL
(216 ? 549 cells/μL) and 443 cells/μL (260? 585 cells/μL),
respectively. These increases were both statistically sig-
nificant (p <0.0001).
For fasting lipid profiles (Total Cholesterol [TC], and
Triglycerides [TG]), TG showed a significant increase
(p = 0.016) from baseline 204 mg/dL (159 ? 290 mg/dL)
to 258 mg/dL (220 ? 374 mg/dL) at week 24, but there
was no significant increase at 48 weeks [267 mg/dL
(166? 302 mg/dL)] (p = 0.372). TC showed no significant
increase at either period. There was no significant increase
in creatinine compared to baseline values (Table 2).
Pain at the site of injection was the main adverse event
in 100% of patients. The other adverse event was the
presence of subcutaneous nodules at the injection siteTable 2 End points after 24 and 48 weeks of treatment
Outcomes Median (IQR)
Baseline W
CD4+ cells count 225 (110? 478) 3
HIV-1 RNA viral load 17,677 (3,702? 92,555) 5
Cholesterol (mg/dL) 174 (154? 196) 1
Triglycerides (mg/dL) 204 (159? 290) 2
Creatinine (mg/dL) 0.9 (0.77? 1.0) 1
*At both 24 and 48 weeks.in 45.4% of the patients. Whereas 19% of patients devel-
oped ISRs, they did not required therapy discontinuation.
Discussion
ENF represented an important breakthrough. It was the
first approved ARV agent belonging to a new drug class
and hence cross-resistance with previous agents was not
a problem. ENF is not used usually in HIV-na?ve pa-
tients except among highly ARV-experienced patients
who do not have another therapy option.
Our study provides additional published data de-
scribing the effectiveness and safety of ENF among
ARV-experienced patients in a clinical setting. Therapy
with ENF-based regimens was associated with high
levels of HIV-1 RNA viral load suppression through 6 and
12 months follow-up, with 91% and 81% in highly
treatment-experienced patients with viral load <400 cop-
ies/mL, and 65.8% and 55.5% <50 copies/mL, respectively,
and was seems to be independent of genotypic sensitivity
score according HIV Stanford database of OBR.
In addition, therapy with ENF was associated with a
median increase in CD4+ cell counts after 6 months and
even greater at 12 months, which is clinically relevant
given the patients ? extensive treatment history and lim-
ited options for background therapy.
Because of the disparity of patient regimens, it is diffi-
cult to determine the contribution made by an individual
agent within the regimen, although, in the mutations
analysis, we can observe that PI score was highly com-
promised; then the role of ENF in reducing viral load in
these patients was likely substantial given their large de-
gree of baseline resistance to the alternative classes.
As predictors of therapeutic success we use GSS,
predictor derived from viral genotype. Including geno-
type information into treatment outcome prediction is
challenging because of the large number of observed mu-
tations and the complexity of the genotype-phenotype re-
lationship, in our study GSS value was not associated with
failure but sample size is not enough for this analysis, and
much less for the analysis by OBR groups.
In addition, the clinical efficacy of ENF has been dem-
onstrated in several studies, in which it was shown to bep value
eek 24 Week 48 24/48 weeks
01 (216? 549) 443 (260? 585) <0.0001*
0 (<50? 137) 50 (<50? 185) <0.0001*
93 (156? 230) 195 (169? 217) 0.158/0.170
58 (220? 374) 267 (166? 302) 0.016/0.372
.0 (0.9? 1.1) 1.0 (0.8? 1.1) 0.157/0.091
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timized background alone (T-20 vs. Optimized Regimen
Only [TORO] studies) in highly treatment-experienced
patients [5,6]. Outside of clinical trials, there are few
published studies with similar results of effectiveness,
durability, and safety of ENF among ARV-experienced
patients in clinical settings. Loutfy et al. found that
therapy with ENF-based regimens for a minimum of
2 months was associated with a 2.53 log(10) viral load de-
crease through 12-month follow-up in a retrospective
cohort of 67 treatment-experienced patients [11]. Belperio
et al. described a cohort of treatment-experienced, older,
HIV-infected patients who received ENF-based regimens:
41% and 55% achieved viral load <400 copies/mL at
6 months and 2 years, respectively (analysis of unique
time period of ENF use before the availability of newer
oral agents indicated for treatment experienced pa-
tients) [12]. In a retrospective monocentric cohort of
18 patients who started ENF and completed at least
3 months of therapy, 11 (61%) patients had HIV-1
RNA viral load <400 copies/mL, among whom eight
(44%) patients had <50 copies/mL in the first 3 months.
The median increase in CD4+ cell count was 159
cells/mm3 (range, 25 to 301) and the median decrease in
HIV-1 RNA viral load was 2.5 ? 1.4 log (10) after 12 months
of ENF-based regimen [13].
As to regimen tolerability, a mild increase in plasma
lipid levels during the initial 24 weeks of treatment was
not sustained at the final follow-up, at variance with
reports elsewhere. Elevation of lipids at baseline may be
attributed to those previous and currently exposure to
PI-based regimens [7,14].
For the injection site reaction, observed at 6 and
12 months, our findings are consistent with previous
studies [15], although the percentages reported by
Cohen et al. were higher [16].
ENF was fairly well tolerated by patients in this study.
Although 19% of patients developed ISRs, it was not as-
sociated with discontinuation therapy. These data differ
from those observed in the TORO studies, in which ISRs
were observed in 98% of patients receiving ENF, leading
to treatment discontinuation in 4.4% of the study partici-
pants [5,6] and Loutfy et al. who reported 52% of their
patients developed ISRs, and 14.1% of the entire cohort
discontinued therapy as a result of ISRs [11].
Despite being a retrospective, descriptive design study
with a small number of patients and lack of a control group
or randomization, this Mexican study also demonstrates
that ENF is a valuable therapy option in highly ARV-
experienced HIV-1-infected patients who have advanced
disease, resistance to traditional ARV drug classes, and clin-
ical progression with very few or no treatment options.
Currently, there is no new different drugs families in
HIV, regarding drugs with different mechanism of actionand no cross-resistance mutations, some people with
HIV multi-drug resistance has only integrase inhibitors
and sometimes CCR5 antagonist or partial activity of a
PI to integrate an OBR; then, ENF will continue as part
of salvage therapy in highly ARV-experienced patients.
ENF has been successfully used to produce durable re-
ductions in viremia even in patients with multi-drug re-
sistance. The likelihood of a sustainable virologic and
immunologic responses is maximized when the patient
has at least 2 other active agents besides ENF in the
OBR, CD4+ cells counts are greater than 100 cells/mm3,
and RNA HIV-1 plasma viral load is less than 100,000
copies/ml.
Despite its adverse injection site effects, the addition
of ENF to an optimized background antiretroviral regi-
men did not exacerbate toxicities associated with anti-
retroviral therapy, and patients treated with enfuvirtide
experienced a significantly lower incidence of diarrhea
and other gastrointestinal side effects.
In conclusion, our study provides clinically important
evidence of the effectiveness and safety of ENF in highly
ARV-experienced HIV-1-infected patients. These find-
ings strengthen the results of previous randomized con-
trolled trials with this agent.
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